At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 100 target
Drug / intervention
sunvozertinib in combination with Anlotinibdrug
Likely dose
sunvozertinib in combination with Anlotinib 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06355609Phase 2RecruitingUpdate OverdueUpdated 21mo ago · Completion was 6mo agoEnrollment Stalled
Update Overdue
A Perspective Observation Phase II, Single-Arm Study Evaluating the 1st Line Efficacy and Safety of Sunvozertinib Plus Anlotinib in EGFR-Sensitive Mutations Combined With Co-Mutations Locally Advanced or Metastatic NSCLC
In Brief
A Phase 2 clinical trial evaluating sunvozertinib in combination with Anlotinib for Non-small Cell Lung Cancer. Currently recruiting, targeting 100 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
This is a phase II, open-label, single-arm, single-center clinical study to evaluate the preliminary efficacy of sunvozertinib in combination with anlotinib in patients with EGFR-sensitive mutations and co-mutations in locally advanced or metastatic treatment-naive non-small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
2025202620272028
First PostedApr 2024
Enrollment StartJul 2024
Primary CompletionDec 2025
TodayJul 2026
Study CompletionDec 2027
First PostedApr 9, 2024
Enrollment StartJul 1, 2024
Primary CompletionDec 30, 2025
Study CompletionDec 30, 2027
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 2.2 years ago
Interventions
sunvozertinib in combination with Anlotinibdrug
Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle.